Verastem Oncology “announced the appointment of John Hayslip, M.D., an accomplished oncologist with deep clinical research, development, and commercialization experience, to chief medical officer where he will lead the Company’s clinical and medical strategy. Dr. Hayslip succeeds Louis J. Denis, M.D., who recently departed the company. Dr. Hayslip has more than 25 years of oncology and research and development experience across industry and academia, most recently serving as the chief medical officer at I-MAB Biopharma. ”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- Verastem Releases Updated Corporate Presentation for Investors
- Verastem announces anti-tumor efficacy of GFH375 at scientific meeting
- Verastem announces inducement grants under Nasdaq listing rule
- Verastem Inc. at a Crossroads: Navigating the Perilous Terrain of Patent Ownership and IP Rights
- Verastem reports Q4 adjusted EPS ($1.10), consensus (62c)
